Agree..... Sanofi has a pathetic track record when it comes to launching new products!
The truth is Sanofi business plan is to buy there way to the top ( buying other companies that do have a pipeline to save their bacon) again, just look at the track record .
I think SNY knows what they have and won't let it slip thru their hands. Al has probably turned down multiple offers and SNY is just putting themselves in a great position by combining their diabetes insulin with Afrezza for maximum control. They don't care if the Afrezza product circumvents some Toujeo sales because in most cases it will be a combination. They will own the space and benefit substantially in this market.
I can't believe the FUD about SNY dropping MNKD in Jan when every barometer shows this is not even feasible. European approval, Global Approval and multiple tests going on by SNY, so why would they drop Afrezza?
Adam Fraudstain continues his drivel and numbers can be twisted to fit one's agenda. Buy all you can at these levels and be rewarded shortly. I will be shocked if this stock is under $6 by the end of this quarter.
Sentiment: Strong Buy
has SNY not properly marketed Afrezza? Hoping MNKD can get away from SNY and partner with another company that would make Afrezza available to patients.
Followed the PennyStock101 (org) newsletter alert on VICT on Friday, and secured some easy double digit same-day gains. They have a new pick coming out tomorrow so I suggest you google "PennyStock101" and sign up for their free newsletter ASAP!
MNKD's new Medical Officer will most definately be an inherent advocate on behalf of PFE.
In fact, maybe he works for PFE and MNKD just entitles him in their behalf?
TS now has numerous RXs in trials a MNKD has selected their "partner" to bring them to fruition.
Is it PFE?
I think so.
SNY and PFE will soon fully control MNKD.
the time is at hand NOW before SNY makes their market blitz.
Once worldwide DTC exposure materializes it will be simply too late and too convoluted to counter attack.
I sincerely believe that the next few weeks will be the pivot point to MNKD's revelation; It can't splash into 2016.
Colton, you over here on the SNY board now Darn it, you've gone free range. Well, I can't blame you, everybody on the MNKD board knows you for a FUDder and have you on ignore there.
But sure folks, email SNY, I'm sure they didn't think through anything about MNKD or Afrezza or it's efficacy, probably didn't even read the contract with MNKD when they signed it, didn't think through their marketing strategy about Toujeo and how Afrezza will dovetail with that nicely and they will most definitely be all "Oh Wow!" and listen to a handful of retail investors on a MB who think they are stupid. (sarcasm).
Sentiment: Strong Buy
Um...it's "Prandial" not "pandrial" and no, they haven't screwed up past launches,and they aren't screwing up this one. The plan is to market Afrezza as an adjunct to Toujeo, the basal insulin. And why would they abandon the PRANDIAL market? Your post makes absolutely no sense.
Call/email Sanofi and demand that they drop Afrezza from their drug line up. Afrezza is resulting in huge losses for Sanofi